In what is being referred to as a “false marketing” scheme, Risperdal manufacturer Johnson & Johnson is facing public scrutiny over the high revenue sales of its schizophrenia medication.
Johnson & Johnson, which is best known for making household products including baby powder and mouthwash, actually makes up 90 percent of their profits based off of their medical devices and drug division.
The company manufactures several commonly prescribed medications including blood thinner Xarelto, diabetes medication Invokana and the schizophrenia treatment Risperdal.
Based on patient population, sales for Johnson & Johnson’s diabetic medication Invokana makes financial sense, as 29 million Americans have been diagnosed with this condition. Within the first quarter of 2015, Invokana had worldwide sales of $278 million.
However, schizophrenia only makes up one percent of the U.S. population yet profits for Risperdal make up a similar amount of annual revenue compared with their diabetes medication, reaching $254 million.
Medical experts state that based on the target audience of schizophrenia patients, Risperdal sales should be significantly lower yet Johnson & Johnson has somehow managed to reach high profits with nine-times fewer potential consumers. This has led to both physicians and patients asking how is this possible?
Risperdal Sales
The answer may be simple. According to multiple judicial judgements, Johnson & Johnson has increasingly marketed Risperdal to patients for uses that the FDA has yet to approve of.
Risperdal was approved by the U.S. Food and Drug Administration to treat schizophrenia in 1994. Since that time, Johnson & Johnson has made numerous attempts to sell the medication to a larger demographic but has been officially denied these requests.
It is federally approved to treat schizophrenic adolescents and adults. However, there has been increasingly more indications of severe side effects showing up in pediatric consumers including gynecomastia (man boobs).
According to studies, Risperdal male breast growth occurs in 30 percent of adolescent boys who take the medication.
Risperdal ‘Man Boobs’ Complications
Studies indicate that Risperdal may increase the levels of prolactin, which stimulates breast growth in women, placing young men between the ages of 10-18 at a greater risk for developing gynecomastia.
However, other Risperdal complications include weight gain so sometimes young men mistake male breast growth for excess fat build-up.
Yet when male patients discontinue the medication, the Risperdal breast tissue growth does not go away. Some plaintiffs even allege that they had to undergo surgery in order to remove Risperdal male breast growth.
Other Risperdal side effects include:
- Breast pain
- Nipple pain
- Nipple discharge
- Milk production
Risperdal Gynecomastia Lawsuits
Currently there are nearly 1,500 lawsuits that claim the medication caused Risperdal man boobs measuring as large as a 46DD cup size.
Two Risperdal lawsuits have gone to trial so far. The first one resulted in a $2.5 million verdict against Johnson & Johnson’s subsidary Janssen Pharmaceuticals. The second resulted in finding Johnson & Johnson failed to warn about gynecomastia risks but rejected claims that Risperdal caused the plaintiff’s medical condition.
Contact a Risperdal attorney to find out if you have legal claim.
Do YOU have a legal claim? Fill out the form on this page now for a free, immediate, and confidential case evaluation. The Risperdal attorneys who work with Top Class Actions will contact you if you qualify to let you know if an individual lawsuit or Risperdal class action lawsuit is best for you. [In general, Risperdal lawsuits are filed individually by each plaintiff and are not class actions.] Hurry — statutes of limitations may apply.
Top Class Actions is a Proud Member of the American Bar Association
LEGAL INFORMATION IS NOT LEGAL ADVICE
Top Class Actions Legal Statement
©2008 – 2015 Top Class Actions® LLC
Various Trademarks held by their respective owners
Get Help – It’s Free
Join a Free Risperdal Class Action Lawsuit Investigation
If you or your son took Risperdal between the ages of 10 and 18 years old and suffered gynecomastia (male breast growth), male breast pain, nipple pain, or nipple discharge, you may be entitled to compensation. See if you qualify by submitting your information below for a free and confidential case review.
An attorney will contact you if you qualify to discuss the details of your potential case at no charge to you.
- First Name*
- Last Name*
- Street Address*
- Apt. #
- City*
- State*
AlabamaAlaskaArizonaArkansasCaliforniaColoradoConnecticutDelawareDistrict of ColumbiaFloridaGeorgiaHawaiiIdahoIllinoisIndianaIowaKansasKentuckyLouisianaMaineMarylandMassachusettsMichiganMinnesotaMississippiMissouriMontanaNebraskaNevadaNew HampshireNew JerseyNew MexicoNew YorkNorth CarolinaNorth DakotaOhioOklahomaOregonPennsylvaniaRhode IslandSouth CarolinaSouth DakotaTennesseeTexasUtahVermontVirginiaWashingtonWest VirginiaWisconsinWyomingArmed Forces AmericasArmed Forces EuropeArmed Forces Pacific
- Zip Code*
- Phone*
- Email*
- If you're filling this out for a loved one, what is the name of the person who took Risperdal?*
- Are you/your loved one a male who took Risperdal between the ages of 10 and 18 years old?*
YesNo
- What year was the person who took Risperdal born?*
- How old was this person when they took Risperdal?*
- Please check the Risperdal injuries suffered:*
-
Breast Growth
-
Breast Pain
-
Nipple Pain
-
Nipple Discharge
-
- How old were you/your loved one when these problems began?*
- ¿Necesita un orador español?
- Yes
- No
- Please enter any additional details you would like the staff reviewing your submission to know.
- I understand and agree that submitting this form does not create an attorney-client relationship and that the information I submit is not confidential or privileged and may be shared.*
-
Yes
-
-
if(typeof gf_global == ‘undefined’) var gf_global = {“gf_currency_config”:{“name”:”U.S. Dollar”,”symbol_left”:”$”,”symbol_right”:””,”symbol_padding”:””,”thousand_separator”:”,”,”decimal_separator”:”.”,”decimals”:2},”base_url”:”http:\/\/topclassactions.com\/wp-content\/plugins\/gravityforms”,”number_formats”:[],”spinnerUrl”:”http:\/\/topclassactions.com\/wp-content\/plugins\/gravityforms\/images\/spinner.gif”};jQuery(document).bind(‘gform_post_render’, function(event, formId, currentPage){if(formId == 25) {gformInitChosenFields(‘#input_25_5′,’No results matched’);if(!/(android)/i.test(navigator.userAgent)){jQuery(‘#input_25_7’).mask(‘(999) 999-9999’).bind(‘keypress’, function(e){if(e.which == 13){jQuery(this).blur();} } );}} } );jQuery(document).bind(‘gform_post_conditional_logic’, function(event, formId, fields, isInit){gformInitChosenFields(‘#input_25_5′,’No results matched’);} ); jQuery(document).ready(function(){jQuery(document).trigger(‘gform_post_render’, [25, 1]) } );
The post Risperdal Sales May Indicate False Marketing Scheme appeared first on Top Class Actions.
No comments:
Post a Comment